Status:
COMPLETED
Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis
Lead Sponsor:
Novartis
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
2-18 years
Phase:
PHASE3
Brief Summary
This study will investigate the steroid sparing effect of pimecrolimus cream 1% in pediatric atopic dermatitis
Eligibility Criteria
Inclusion
- Outpatients aged 2 to \< 18 years with severe AD (score 8 or 9 according to Rajka and Langeland)
- responded to 21 days of treatment with prednicarbate cream 0.25% during screening phase
Exclusion
- Patients who had received phototherapy, systemic or topical therapy or systemic corticosteroids shortly prior to study
Key Trial Info
Start Date :
December 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2004
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT00351052
Start Date
December 1 2001
End Date
September 1 2004
Last Update
January 17 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site, Germany